Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H53N2O4.Br |
Molecular Weight | 609.678 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])C[C@H](O)[C@H](C[C@]34C)N5CCOCC5)[N+]6(CC=C)CCCC6
InChI
InChIKey=OYTJKRAYGYRUJK-FMCCZJBLSA-M
InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1
Molecular Formula | C32H52N2O4 |
Molecular Weight | 528.7663 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://reference.medscape.com/drug/zemuron-rocuronium-343109 | https://www.drugs.com/pro/rocuronium-bromide-injection.html | https://www.drugbank.ca/drugs/DB00728 | https://www.ncbi.nlm.nih.gov/pubmed/2573387 | https://www.ncbi.nlm.nih.gov/pubmed/21568994
Curator's Comment: description was created based on several sources, including
http://reference.medscape.com/drug/zemuron-rocuronium-343109 | https://www.drugs.com/pro/rocuronium-bromide-injection.html | https://www.drugbank.ca/drugs/DB00728 | https://www.ncbi.nlm.nih.gov/pubmed/2573387 | https://www.ncbi.nlm.nih.gov/pubmed/21568994
Rocuronium (brand names Zemuron, Esmeron) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anesthesia to facilitate endotracheal intubation by providing skeletal muscle relaxation, most commonly required for surgery or mechanical ventilation. Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Most common adverse reactions are transient hypotension and hypertension.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362997 |
8.6 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZEMURON Approved UseRocuronium bromide injection is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium bromide is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. (1) Launch Date1994 |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.4 h |
0.6 mg/kg single, intravenous dose: 0.6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ROCURONIUM unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.9 h |
0.45 mg/kg single, intravenous dose: 0.45 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ROCURONIUM unknown | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
70% |
0.6 mg/kg single, intravenous dose: 0.6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ROCURONIUM unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.15 mg/kg single, intravenous Recommended Dose: 0.15 mg/kg Route: intravenous Route: single Dose: 0.15 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 64 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 64 Sources: |
Other AEs: Procedural pain, Vomiting... |
0.45 mg/kg single, intravenous Recommended Dose: 0.45 mg/kg Route: intravenous Route: single Dose: 0.45 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 63 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 63 Sources: |
Other AEs: Procedural pain, Vomiting... Other AEs: Procedural pain (14%) Sources: Vomiting (6%) Procedural hypotension (5%) |
0.6 mg/kg single, intravenous Recommended Dose: 0.6 mg/kg Route: intravenous Route: single Dose: 0.6 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 66 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 66 Sources: |
Other AEs: Procedural pain, Vomiting... Other AEs: Procedural pain (17%) Sources: Vomiting (8%) Procedural hypotension (5%) Nausea (5%) |
1 mg/kg single, intravenous Recommended Dose: 1 mg/kg Route: intravenous Route: single Dose: 1 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 56 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 56 Sources: |
Other AEs: Procedural pain, Vomiting... Other AEs: Procedural pain (18%) Sources: Vomiting (12%) Procedural hypotension (4%) Nausea (4%) |
10 ug/kg/min single, intravenous Recommended Dose: 10 ug/kg/min Route: intravenous Route: single Dose: 10 ug/kg/min Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 73 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 73 Sources: |
Other AEs: Procedural pain, Hypercapnia... Other AEs: Procedural pain (12%) Sources: Hypercapnia (3%) Nausea (3%) |
0.6 mg/kg single, intravenous Recommended Dose: 0.6 mg/kg Route: intravenous Route: single Dose: 0.6 mg/kg Co-administed with:: midazolam(1-2 mg) Sources: propofol(1.8 mg/kg) alfentanil(9 ug/kg) |
unhealthy, 33.1 n = 20 Health Status: unhealthy Condition: surgical procedures Age Group: 33.1 Sex: F Population Size: 20 Sources: |
Other AEs: Nausea and vomiting... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Procedural pain | 14% | 0.15 mg/kg single, intravenous Recommended Dose: 0.15 mg/kg Route: intravenous Route: single Dose: 0.15 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 64 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 64 Sources: |
Vomiting | 3% | 0.15 mg/kg single, intravenous Recommended Dose: 0.15 mg/kg Route: intravenous Route: single Dose: 0.15 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 64 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 64 Sources: |
Procedural pain | 14% | 0.45 mg/kg single, intravenous Recommended Dose: 0.45 mg/kg Route: intravenous Route: single Dose: 0.45 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 63 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 63 Sources: |
Procedural hypotension | 5% | 0.45 mg/kg single, intravenous Recommended Dose: 0.45 mg/kg Route: intravenous Route: single Dose: 0.45 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 63 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 63 Sources: |
Vomiting | 6% | 0.45 mg/kg single, intravenous Recommended Dose: 0.45 mg/kg Route: intravenous Route: single Dose: 0.45 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 63 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 63 Sources: |
Procedural pain | 17% | 0.6 mg/kg single, intravenous Recommended Dose: 0.6 mg/kg Route: intravenous Route: single Dose: 0.6 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 66 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 66 Sources: |
Nausea | 5% | 0.6 mg/kg single, intravenous Recommended Dose: 0.6 mg/kg Route: intravenous Route: single Dose: 0.6 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 66 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 66 Sources: |
Procedural hypotension | 5% | 0.6 mg/kg single, intravenous Recommended Dose: 0.6 mg/kg Route: intravenous Route: single Dose: 0.6 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 66 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 66 Sources: |
Vomiting | 8% | 0.6 mg/kg single, intravenous Recommended Dose: 0.6 mg/kg Route: intravenous Route: single Dose: 0.6 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 66 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 66 Sources: |
Vomiting | 12% | 1 mg/kg single, intravenous Recommended Dose: 1 mg/kg Route: intravenous Route: single Dose: 1 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 56 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 56 Sources: |
Procedural pain | 18% | 1 mg/kg single, intravenous Recommended Dose: 1 mg/kg Route: intravenous Route: single Dose: 1 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 56 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 56 Sources: |
Nausea | 4% | 1 mg/kg single, intravenous Recommended Dose: 1 mg/kg Route: intravenous Route: single Dose: 1 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 56 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 56 Sources: |
Procedural hypotension | 4% | 1 mg/kg single, intravenous Recommended Dose: 1 mg/kg Route: intravenous Route: single Dose: 1 mg/kg Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 56 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 56 Sources: |
Procedural pain | 12% | 10 ug/kg/min single, intravenous Recommended Dose: 10 ug/kg/min Route: intravenous Route: single Dose: 10 ug/kg/min Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 73 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 73 Sources: |
Hypercapnia | 3% | 10 ug/kg/min single, intravenous Recommended Dose: 10 ug/kg/min Route: intravenous Route: single Dose: 10 ug/kg/min Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 73 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 73 Sources: |
Nausea | 3% | 10 ug/kg/min single, intravenous Recommended Dose: 10 ug/kg/min Route: intravenous Route: single Dose: 10 ug/kg/min Co-administed with:: sevoflurane(2-2.5 MAC) Sources: |
unhealthy, 0-17 n = 73 Health Status: unhealthy Condition: surgical procedures Age Group: 0-17 Sex: M+F Population Size: 73 Sources: |
Nausea and vomiting | 2 patients | 0.6 mg/kg single, intravenous Recommended Dose: 0.6 mg/kg Route: intravenous Route: single Dose: 0.6 mg/kg Co-administed with:: midazolam(1-2 mg) Sources: propofol(1.8 mg/kg) alfentanil(9 ug/kg) |
unhealthy, 33.1 n = 20 Health Status: unhealthy Condition: surgical procedures Age Group: 33.1 Sex: F Population Size: 20 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A101) 1, (PMDA_K101) 13 |
unlikely | |||
Page: (PMDA_A100) 18 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Nondepolarizing neuromuscular blockers inhibit the serotonin-type 3A receptor expressed in Xenopus oocytes. | 2000 Feb |
|
Recovery of neuromuscular block in morbidly obese patients following an infusion of rocuronium. | 2001 |
|
Anaesthetic management of an adolescent for scoliosis surgery with a Fontan circulation. | 2001 |
|
Use of remifentanil in combination with desflurane or propofol for ambulatory oral surgery. | 2001 |
|
Anesthesia for Cesarean section and posterior fossa craniotomy in a patient with von Hippel-Lindau disease. | 2001 Apr |
|
Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol. | 2001 Apr |
|
Rocuronium-induced neuromuscular blockade is affected by chronic phenytoin therapy. | 2001 Apr |
|
Postoperative residual block after intermediate-acting neuromuscular blocking drugs. | 2001 Apr |
|
Increased sensitivity to depolarization and nondepolarizing neuromuscular blocking agents in young rat hemidiaphragms. | 2001 Aug |
|
Transcranial Doppler ultrasonography with induction of anesthesia and neuromuscular blockade in surgical patients. | 2001 Aug |
|
A double-blind, randomized comparison of low-dose rocuronium and atracurium in a desflurane anesthetic. | 2001 Aug |
|
Safety and efficacy of rocuronium for controlled intubation with paralytics in the pediatric emergency department. | 2001 Aug |
|
The pharmacoeconomics of neuromuscular blocking drugs: a perioperative cost-minimization strategy in children. | 2001 Aug |
|
The new neuromuscular blocking agents: do they offer any advantages? | 2001 Dec |
|
Propofol anaesthesia via target controlled infusion or manually controlled infusion: effects on the bispectral index as a measure of anaesthetic depth. | 2001 Dec |
|
Equi-lasting doses of rocuronium, compared to mivacurium, result in improved neuromuscular blockade in patients undergoing gynecological laparoscopy : [Des doses de durée équivalente de rocuronium, comparé au mivacurium, améliorent la curarisation chez des patientes qui subissent une laparoscopie gynécologique]. | 2001 Dec |
|
[Sevoflurane augments the degree and speeds the onset of rocuronium evoked neuromuscular blockade in children]. | 2001 Dec |
|
The effect of rocuronium on intraocular pressure: a comparison with succinylcholine. | 2001 Dec |
|
Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients: the influence of cardiac output. | 2001 Jan |
|
Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. | 2001 Jul |
|
Intubating conditions after three different doses of rocuronium in the elderly. | 2001 Jun |
|
The effects of remifentanil on haemodynamic stability during rigid bronchoscopy. | 2001 Jun |
|
Effectiveness and safety of rocuronium-hypnotic sequence for rapid-sequence induction. | 2001 Mar |
|
Pediatric renal transplantation: anesthesia and perioperative complications. | 2001 Mar |
|
The prone position is associated with a decrease in respiratory system compliance in healthy anaesthetized infants. | 2001 May |
|
Onset and duration of action of rocuronium--from tracheal intubation, through intense block to complete recovery. | 2001 May |
|
Rocuronium and anaphylaxis--a statistical challenge. | 2001 Nov |
|
Reexamined: the recommended endotracheal intubating dose for nondepolarizing neuromuscular blockers of rapid onset. | 2001 Oct |
|
Incidence of UK reactions involving rocuronium may simply reflect market use. | 2001 Sep |
|
Effect of ondansetron pretreatment on pain after rocuronium and propofol injection: a randomised, double-blind controlled comparison with lidocaine. | 2001 Sep |
|
Effect of 17 beta-estradiol-D-17 beta-glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates. | 2002 Feb |
|
Population pharmacodynamic modeling without plasma concentrations of rocuronium in children. | 2002 Jan |
|
[Anaphylaxis after rocuronium: advantage of blood tests for early diagnosis]. | 2002 Mar |
|
Prolonged neuromuscular block after rocuronium in postpartum patients. | 2002 Mar |
Patents
Sample Use Guides
0.45-0.6 mg/kg IV
Maintenance: 0.1-0.2 mg/kg IV repeat PRN OR
Continuous infusion: 0.01-0.012 mg/kg/min IV
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21568994
Aliquots of 100 mkl whole heparinized blood of rocuronium-allergic patients (positive basophil activation test and skin test) were challenged at 37 C with buffer as a negative control, anti-IgE (Pharmingen,BDBioscience, Erembodegem, Belgium) as a positive control, serial dilutions of rocuronium (Esmeron, Organon, Brussels, Belgium, 0.2–2.0 x 10^3 mkg/ml), serial dilutions of sugammadex (Bridion; Merck Sharp & Dohme, Oss, The Netherlands) 0.2–2.0 x 10^3 mkg/ml and with a mixture of different concentrations of rocuronium and sugammadex. Flow cytometric analysis of basophils was performed using triple labelling with CD123-PE, HLA-DR-PerCP, CD63-FITC (BD Biosciences) and using monoclonal antihuman IgE (clone GE-1; Sigma-Aldrich Chemic GmBH, Steinheim, Germany), labelled with AlexaFluor 488 (Molecular Probes, Invitrogen, Paisley, UK). Samples were analysed on a flow cytometer (FACsCanto BD; Immunocytometry Systems, San Jose, CA, USA) and expressed as CD63-positive basophils. Samples were regarded as positive when CD63-reactive basophils were higher than 4%
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:46:51 GMT 2023
by
admin
on
Fri Dec 15 15:46:51 GMT 2023
|
Record UNII |
I65MW4OFHZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM03AC09
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
||
|
WHO-ATC |
M03AC09
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
||
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ROCURONIUM BROMIDE
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
I65MW4OFHZ
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
119302-91-9
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
m9645
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
32521
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID7023566
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201244
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
441351
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
SUB10353MIG
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
6864
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
DBSALT000575
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
1604905
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
8885
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
I65MW4OFHZ
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
C47709
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY | |||
|
100000080269
Created by
admin on Fri Dec 15 15:46:51 GMT 2023 , Edited by admin on Fri Dec 15 15:46:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |